Association between methylenetetrahydrofolate reductase gene C677T polymorphism and susceptibility to polycystic ovary syndrome

Vandana Rai, Pradeep Kumar

Department of Biotechnology
VBS Purvanchal University
Jaunpur -222003, India.

E mail- raivandana@rediffmail.com

Abstract:

Polycystic ovary syndrome (PCOS) is the most common form of endocrinopathy of women. Several studies have investigated the association of methylenetetrahydrofolate reductase (MTHFR) gene C677T polymorphism with PCOS risk but the results are contradictory. So, the aim of the present study was to carry out a meta-analysis of a published case control studies to find out exact association between MTHFR gene C677T polymorphism and PCOS susceptibility. Pubmed, Springer link, Science Direct and Google Scholar databases were searched for case-control studies. Odds ratios (ORs) with 95% confidence intervals (CIs) was used as association measure and meta-analysis was performed using MIX and MetaAnalyst programs.

Meta-analysis of 24 studies showed strong significant association between C677T polymorphism and PCOS risk (for T vs. C: OR= 1.18, 95% CI=1.01-1.38, p=0.03; for TT vs. CC: OR= 1.37, 95% CI=1.0-1.89, p= 0.045; for TT + CT vs. CC: OR= 1.31, 95% CI= 1.07-1.62, p= 0.008; for CT vs. CC: OR= 1.31, 95% CI= 1.04-1.62, p= 0.01 and for TT vs. CT + CC: OR= 1.10, 95% CI= 0.82-1.47, p= 0.04). In subgroup analysis, MTHFR C677T polymorphism is significantly associated with PCOS risk with Asian individuals but in Caucasian population MTHFR C677T polymorphism was not significantly associated with PCOS risk. In conclusion, C677T polymorphism is a risk factor for PCOS.

Keywords:

Polycystic Ovary Syndrome, PCOS, PCOD, MTHFR, C677T, meta-analysis

Introduction:

Polycystic ovary syndrome (PCOS) also known as polycystic ovary disease (PCOD) is the most common and widespread form of endocrinopathy of women of fertile, affecting up to 2 - 25% of women in reproductive age (Wijeyaratne et al., 2002). PCOS is characterized by oligomenorrhea or amenorrhea and hyperandrogenism (Fauser et al., 2004). It is associated with increased risk of pregnancy loss (Chang 2014). PCOS is a mutimetabolic syndrome and a risk factor for the obesity, type 2 diabetes, hypertension and dyslipidaemia (Wild et al., 1985; Talbott et al., 1995; Solomon, 1999). According to Rotterdam consensus (2003) diagnostic criteria, minimum two symptoms of the following should be present 1) clinical hyperandrogenism 2) oligoanovulation and 3) polycystic ovaries (PCO).

PCOS is a heterogeneous condition and earlier evidences and reports have suggested that the disturbed homocysteine (Hcy) methionine cycle increases concentration of homocysteine in the women, and higher concentration of homocystein is a risk factor for PCOS. Environmental and genetic factors play an important role in Hcy synthesis. Hcy is a sulfur containing amino acid and is converted into methionine in folate and methionin cycle. Methylenetetrahydrofolate reductase (MTHFR) enzyme is involved in the folate dependent remethylation of Hcy to methionine (Wu et al. 2012) and single nucleotide polymorphism (SNP) in MTHFR gene is the most common genetic defect of homocysteine metaboism. It catalyzes the conversion of 5,10-methylenetetrahydrofolate into 5-methylenetetrahydrofolate, which provides a single carbon for the methylation of homocysteine to methionine (Wu et al. 2012). C677T polymorphism (rs1801133) involves cytosine-to-thymine substitution at the 677 position (C677T), leads to an alanine-to-valine substitution at position 222 in the MTHFR enzyme. C677T polymorphism leads to thermolability of MTHFR enzyme, resulting in decreased enzyme activity (Frosst et al.,1995; Jacques et

al. 1996). Frequency of C677T polymorphism is greatly varies in different global regions (Schneider et al., 1998; Wilcken et al., 2003; Spiridonova et al., 2004; Rai et al., 2010, 2012; Yadav et al., 2018).

First of all, Glueck and colleagues (1999) have reported an association between MTHFR C677T polymorphism and PCOS. Since then, several reports are published regarding MTHFR C677T polymorphism as a risk factor for PCOS with positive (Wu et al., 2016; Jiao et al., 2018; Amuhtar and Amohaidi, 2019) as well as negative (Sills et al., 2001; Lee et al., 2003; Orio et al., 2003) results. Hence, the aim of the present study was to explore whether the MTHFR C677T polymorphism is associated with susceptibility to polycystic ovary syndrome (PCOS). In the present study, authors have performed a large-scale meta-analysis to find out the exact association between the MTHFR C677T polymorphism and PCOS by including data from studies that were published from 1999 until now.

Methods:

Article Search.

Published articles examining the effect of the MTHFR gene C677T polymorphisms on the risk of PCOS were identified through electronic database searches in Pubmed, Science direct, Google scholar and Springer Link. Databases searches were done from January 1990. Electronic database searches were supplemented by manual searches of references of review and published research articles. The following terms were used: “methylenetetrahydrofolate reductase”, “MTHFR,” “C677T”, “polycystic ovary syndrome” “polycystic ovary disease”, “PCOS”, “PCOD”, “polymorphism”. Literature search included all languages. If any study included different sample groups, authors have considered each sample group as a separate study in the meta-analysis.

Inclusion criteria

Studies included in our meta-analyses were based on the following criteria: (1) published in a peer-reviewed journal, (2) detailed description of the samples tested (including sample size, ancestry of samples); and (3) data published before December 31, 2019. Articles were excluded if: (1) sample was not independent, (2) incomplete data/information, (3) family-based studies and genome-wide association studies (4) review, letter to editors and book chapters etc.

Data Extraction

Name of first author, ethnicity, country name, number of controls and cases, and number of MTHFR genotypes in PCOS cases and Controls were extracted from each selected article.

Statistical Analyses:

Meta-analysis was done according to the method of Rai et al (2014). Pooled ORs were estimated by using fixed effects (Mantel and Haenszel, 1959) and random effects (DerSimonian and Laird, 1986) model depending upon heterogeneity. When there is considerable heterogeneity between studies then the pooled OR is preferably estimated using the RE model (Zintzaras and Ioannidis, 2005). The between studies heterogeneity was calculated and was quantified using the I^2 statistic (Higgins and Thompson, 2002). Sensitivity analysis was performed to evaluate by removing the studies not in Hardy–Weinberg equilibrium (HWE). Control population of each study was tested for Hardy–Weinberg Equilibrium (HWE) using calculator available at <http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>. Publication bias was assessed by Egger regression asymmetry test (Egger et al., 1997). P values were two-tailed with a significance level of 0.05. All statistical analyses were performed using computer programs Meta-Analyst (Wallace et al., 2013) and Mix version 1.7 (Bax et al., 2006).

Results:

Literature Search:

Electronic database search yielded 161 studies, after applying strict inclusion and exclusion criteria total 23 articles were found suitable for the inclusion in the present meta-analysis. Figure 1 shows the different phases of the study selection. Information was collected from 22 articles that associated MTHFR gene C677T polymorphism and PCOS (Glueck et al., 1999; Sills et al., 2001; Tsanadis et al., 2002; Lee et al., 2003; Orio et al., 2003; Palep-Singh et al., 2007; Choi et al., 2009; Bayram et al., 2010; Karadeniz et al., 2010; Idali et al., 2012; Jain et al., 2012; Kazeerooni et al., 2013; Jiang et al., 2015; Naghavi et al., 2015; Qi et al., 2015; Carlus et al., 2016; Geng et al., 2016; Ozegowska et al., 2016; Sazafarowska et al., 2016; Wu et al., 2016; Jiao et al., 2018; Amuhtar and Amohaidi, 2019) (Table 1). In two studies, authors

(Palep-Singh et al., 2007; Carlus et al., 2016) included two group of samples.. So, in present meta-analysis, both dataset were included as separate study, and the number of included studies were twenty four.

Characteristic of Eligible Studies:

The included studies were published between 1999 and 2019. A total of 2562 cases and 2587 controls were analyzed. The analysis included Caucasian samples in 10 studies and Asian samples in 14 studies (Table 1).

The prevalence of homozygotes (CC) among PCOS cases and healthy controls were 41.64% and 49.67%, respectively. The prevalence of heterozygotes (CT) among PCOS patients and controls were 41.26% and 36.72%, respectively. The prevalence of mutant homozygote (TT) among PCOS cases and the controls were 17.45% and 14.15%, respectively. In the PCOS cases, C allele was the most frequent: 62.06% whereas the frequency of the T allele was 37.94%. In the control group, the prevalence of C allele was 67.67%, and the prevalence of T allele was 32.33% (Figure 2). In four studies (Bayram et al., 2010; Karadeniz et al., 2010; Kazeerooni et al., 2013; Ozegowska et al., 2015), control genotypes were not in Hardy–Weinberg equilibrium ($P < 0.05$). All genetic models; -allele contrast (T vs C) homozygote (TT vs CC), co-dominant (CT vs CC), dominant (TT+CT vs CC) and recessive (TT vs CT+CC) models were used to evaluate C677T polymorphism as PCOS risk.

Meta-analysis:

Table 2 summarizes the ORs with corresponding 95% CIs for association between T polymorphism and risk of PCOS in allele contrast, co-dominant, homozygote dominant, and recessive models. Meta-analysis of allele contrast (T vs. C) model showed significant association with both fixed effect ($OR_{TvsC} = 1.28$; 95%CI= 1.17-1.40; $p = < 0.0001$) and random effect model ($OR_{TvsC} = 1.18$; 95%CI= 1.01-1.38; $p = 0.03$). Subjects with PCOS cases showed a significantly increased frequency of the T allele in comparison to control. (Table 2).

Meta-analysis of twenty five studies showed an increased risk of PCOS among mutant homozygote variants (TT vs. CC; homozygote model), with both fixed ($OR_{TTvsCC} = 1.62$; 95%CI= 1.34-1.96; $p < 0.0001$) and random ($OR_{TTvsCC} = 1.39$; 95%CI= 1.0-1.89; $p = 0.04$) effect models (Table 2, Figure 3). Association of heterozygous genotype (CT vs. CC; co-dominant model) was also observed significant with both fixed ($OR_{CTvsCC} = 1.34$; 95%CI= 1.17-1.59; $p < 0.0001$) and random ($OR_{CTvsCC} = 1.31$; 95%CI= 1.04-1.62; $p = 0.02$) effect models (Table 2). Combined mutant genotypes (TT + CT vs. CC; dominant model) showed positive association with PCOS using both fixed ($OR_{TT+CTvsCC} = 1.39$; 95%CI= 1.23-1.58; $p < 0.0001$) and random ($OR_{TT+CTvsCC} = 1.31$; 95%CI= 1.07-1.62; $p = 0.008$) effect models (Table 2). Similarly the recessive genotypes model (TT vs. CT + CC) also showed positive association with PCOS using both fixed ($OR_{TTvsCT+CC} = 1.32$; 95%CI= 1.12-1.55; $p = 0.0007$) and random ($OR_{TTvsCT+CC} = 1.10$; 95%CI= 0.82-1.47; $p = 0.041$) effect models (Table 2).

Sub-group Analysis:

Out of 24 studies 16 studies (2023 cases and 1959 controls) were Asian region and 8 studies (539 cases and 628 controls) from Caucasian population. Meta-analysis of Asian studies revealed that except recessive model, a other four models showed significant association between MTHFR C677T polymorphism and PCCOS risk (for T vs. C: $OR = 1.29$, 95% CI=1.06-1.57, $p = 0.03$; for TT vs. CC: $OR = 1.38$, 95% CI=0.91-2.11, $p = 0.05$; for TT + CT vs. CC: $OR = 1.48$, 95% CI= 1.13-1.92, $p = 0.004$; for CT vs. CC: $OR = 1.49$, 95% CI= 1.12-1.92, $p = 0.005$ and for TT vs. CT + CC: $OR = 1.08$, 95% CI= 0.74-1.58, $p = 0.68$) (Figure 4).

Meta-analysis of Caucasian studies did not show any association between PCOS susceptibility and MTHFR C677T polymorphism (for T vs. C: $OR = 1.04$, 95% CI= 0.83-1.30, $p = 0.31$; for TT + CT vs. CC: $OR = 1.07$, 95% CI= 0.85- 1.35, $p = 0.54$; for TT vs. CC: $OR = 1.29$, 95% CI= 0.87-1.91, $p = 0.19$) (Figure 5).

Heterogeneity analysis:

A true heterogeneity existed between studies in allele contrast ($P_{heterogeneity} = < 0.001$, $Q = 59.15$, $df = 24$, $I^2 = 61.12\%$, $t^2 = 0.08$), co-dominant ($P_{heterogeneity} = 0.0002$, $Q = 54.65$, $df = 24$, $I^2 = 57.92\%$, $t^2 = 0.15$),

homozygote ($P_{\text{heterogeneity}} = 0.001$, $Q = 44.74$, $df = 24$, $I^2 = 53.06\%$, $t^2 = 0.25$) and dominant genotypes ($P_{\text{heterogeneity}} = 0.0002$, $Q = 54.74$, $df = 24$, $I^2 = 57.99\%$, $t^2 = 0.14$) comparisons. The ' I^2 ' value was more than 50% in allele and a genotype comparisons, showed high level of true heterogeneity. Allele contrast meta-analysis of Asian studies showed significant higher heterogeneity ($P_{\text{heterogeneity}} = 0.0004$, $I^2 = 69.39\%$), but in Caucasian studies meta-analysis true heterogeneity was absent ($P_{\text{heterogeneity}} = 0.34$, $I^2 = 11.06\%$).

Sensitivity analysis:

In sensitivity analysis, allele contrast meta-analysis was performed after exclusion of four studies (Bayram et al., 2010; Karadeniz et al., 2010; Kazeerooni et al., 2013; Ozegowska et al., 2015) in which control population was not in HWE. Exclusion of four studies not in HWE did not affect heterogeneity and also did not increase the odds ratio.

Publication bias:

Precision and standard error Funnel plots are symmetrical and p-value of Eggers test, is higher than 0.05 (except recessive mode), showing the absence of publication bias (for T vs. C: $P_{\text{pb}} = 0.07$; for CT vs. CC: $P_{\text{pb}} = 0.77$; for TT vs. CC: $P_{\text{pb}} = 0.05$; for TT+CT vs. CC: $P_{\text{pb}} = 0.41$; and for TT vs. CT + CC: $P_{\text{pb}} = 0.01$) (Figure 6).

Discussion:

Several experimental and clinical evidences suggested that disturbances in folate (either deficiency or excess) and homocystein-methionine cycles resulted in ovarian dysfunctions-(i) ovulation in immature superovulated rats inhibited (Willmott et al., 1968; Wang et al., 2017) ,(ii) monkeys have degenerated Graffian follicles and an increase in atretic and cystic follicles (Mohanty and Das,1982; Wang et al., 2017) and (iii) homocysteine levels in PCOS cases and homocysteine levels returned to normal levels following folic acid supplementation (Bayraktar et al., 2004; Badawy et al., 2007; Kazerooni et al., 2007 ; Wang et al., 2017). In present meta-analysis, we tried to find out the exact associations between MTHFR C677T polymorphism and PCOS susceptibility. Our results indicated that the MTHFR polymorphism is risk factor for PCOS and OR is statistically significant (OR = 1.31; 95% CI= 1.07-1.62; $p = 0.008$).

Meta-analysis is a powerful strategy to find out the effects of genes in susceptibility of different diseases/disorders. In past two decades, numerous meta-analysis were published to evaluate the risk of genes polymorphism for different disease/ disorders- MTRR gene frequency (Yadav et al.,2019), down syndrome (Rai,2011; Rai et al., 2017; Rai and Kumar, 2018), cleft lip and palate (Rai, 2017), Glucose-6-phosphate dehydrogenase deficiency (Kumar et al.,2016), recurrent pregnancy loss (Rai,2014,2016), male infertility (Rai and Kumar, 2017), autism (Rai, 2016), schizophrenia (Rai et al., 2017), obsessive compulsive disorder (Kumar and Rai,2019), depression (Rai,2014,2017), epilepsy (Rai and Kumar,2018), Alzheimers disease (Rai, 2016), esophageal cancer (Kumar and Rai, 2018), prostate cancer (Yadav et al.,2016), breast cancer (Rai et al.,2017), endometrial cancer (Kumar et al., 2018) colorectal cancer (Rai, 2015), uterine leiomyoma (Kumar and Rai,2018),and ovary cancer (Rai , 2016).

Several limitations of this meta-analysis should be considered such as (i) crude OR calculated, (ii) presence of higher between heterogeneity, and (iii) included single gene polymorphism. In addition to limitations, present meta-analysis also have several strengths like- absence of publication bias, inclusion of large number of studies as well as large sample size.

In conclusion, the results indicate that the MTHFR C677T polymorphism is risk factor for PCOS (OR = 1.31; $p = 0.008$). Subgroup analysis based on ethnicity also confirmed the results that MTHFR C677T polymorphism is risk factor for PCOS in Asians but not in Caucasian population. In future, Studies with larger sample sizes from different population of globe are required to come to conclusion regarding MTHFR C677T polymorphism and PCOS association.

Compliance with Ethical Standards:

Conflict of Interest: None

Informed consent and Ethical Clearance are not required , as there was no human or animal involment in the present study

Sources of financial support: Nil

References:

Almukhtar AA, Almohaidi AMS.2019. Investigation for variation in *MTHFR* gene in iraqi arab female with PCOS. *Asian Jr. of Microbiol. Biotech. Env. Sc.* 21. (4) : 851-861

Badawy A, State O, El Gawad SSA, El Aziz OA. Plasma homocysteine and polycystic ovary syndrome: the missed link. *Eur J Obstet Gynecol Reprod Biol.* 2007; 131:68–72.

Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KG (2006) Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. *BMC Med Res Methodol* 6:50-58.

Bayraktar F, Dereli D, Ozgen AG, Yilmaz C. Plasma homocysteine levels in polycystic ovary syndrome and congenital adrenal hyperplasia. *Endocr J* 2004;51:601–608.

Carlus SJ, Sarkar S, Bansal SK, Singh V, Singh K, Jha RK, Sadasivam N, Sadasivam SR, Gireesha PS, Thangaraj K, Rajender S. Is *MTHFR* 677 C>T Polymorphism Clinically Important in Polycystic Ovarian Syndrome (PCOS)? A Case-Control Study, Meta-Analysis and Trial Sequential Analysis. *PLoS One.* 2016; 11:e0151510.

Chan Y, Zi F, Wu X, Ma L, Meng Y, Chen J (2012). Note of clarification of data in the meta-analysis of methylenetetrahydrofolate reductase C677T polymorphisms in polycystic ovary syndrome. *Mol Hum Reprod.* 18: 514–515.

Chang RJ (2014). Polycystic Ovary Syndrome and Hyperandrogenic States. *Yen & Jaffe's Reproductive Endocrinology.* Strauss JS, Barbieri RL. Philadelphia, Elsevier/Saunders, p. 485.

Choi SW, Gu BH, Ramakrishna S, Park JM, Baek KH. Association between a single nucleotide polymorphism in *MTHFR* gene and polycystic ovary syndrome. *Eur J Obstet Gynecol Reprod Biol.* 2009; 145:85–8.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. *Controlled Clin Trials* 7: 177-188.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. *BMJ* 315: 629-34.

ESHRE Capri Workshop Group. Hormones and cardiovascular health in women. *Hum Reprod Update* 2006;12(5):483–497.

Fauser BCJM, Chang J, Azziz R, Lobo R. 2004.Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). *Human Reproduction* 19(1):41-47.

Forges T, Monnier-Barbarino P, Alberto JM, Guéant-Rodriguez RM, Daval JL, Guéant JL. Impact of folate and homocysteine metabolism on human reproductive health. *Hum Reprod Update* 2007;13:225–238.

Framingham Offspring Study. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study. *Diabetes Care* 2001;24(8):1403–1410.

Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. *Nat Genet.* 1995; 10:111–3.

Fu LY, Dai LM, Li XG, Zhang K, Bai Y (2014). Association of methylenetetrahydrofolate reductase gene C677T polymorphism with polycystic ovary syndrome risk: a systematic review and metaanalysis update. *Eur J Obstet Gynecol Reprod Biol.* 172: 56–61.

Geng J, Zhang C, Hu S, Zhang Y, Zhang S, Lu J, Xie J, Zhao H. Role of methylenetetrahydrofolate reductase genetic polymorphisms in polycystic ovary syndrome risk. *Int J Clin Exp Pathol.* 2016; 9:8532–7.

Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Tracy T, Moore SK (1999). Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. *Metabolism.* 48: 1589–1595.

Gmyrek GB, Sozanski R, Jerzak M, Chrobak A, Wickiewicz D, Skupnik A, et al. (2005). Evaluation of monocyte chemotactic protein-1 levels in peripheral blood of infertile women with endometriosis. *Eur J Obstet Gynecol Reprod Biol.* 122: 199–205.

Gul OB, Somunkiran A, Yucel O, Demirci F, Ozdemir I. The effect of ethinyl estradiol-cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndrome. *Arch Gynecol Obstet* 2008;277:25–30.

Guzelmeric K, Alkan N, Pirimoglu M, Unal O, Turan C. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome. *Gynecol Endocrinol* 2007;23:505–510.

Hak AE, Polderman KH, Westendorp IC, Jakobs C, Hofman A, Witteman JC, Stehouwer CD. Increased plasma homocysteine after menopause. *Atherosclerosis* 2000;149:163–168.

Henning BF, Tepel M, Riezler R, Gillessen A, Doberauer C. Vitamin supplementation during weight reduction—favourable effect on homocysteine metabolism. *Res Exp Med (Berl)* 1998;198:37–42.

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. *Stat Med* 21: 1539–1558.

Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. *JAMA* 2002;288(16):2015–2022.

Idali F, Zareii S, Mohammad-Zadeh A, Reihany-Sabet F, Akbarzadeh-Pasha Z, Khorram-Khorshid HR (2012). Plasminogen activator inhibitor 1 and methylenetetrahydrofolate reductase gene mutations in iranian women with polycystic ovary syndrome. *Am J Reprod Immunol.* 68: 400–407.

Isotalo PA, Wells GA, Donnelly JG (2000). Neonatal and fetal methylenetetrahydrofolate reductase genetic polymorphisms: an examination of C677T and A1298C mutations. *Am J Hum Genet.* 67: 986–90.

Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, et al. (1996). Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. *Circulation*. 93: 7–9.

Jain M, Pandey P, Tiwary NK, Jain S. MTHFR C677T polymorphism is associated with hyperlipidemia in women with polycystic ovary syndrome. *J Hum Reprod Sci*. 2012; 5:52–6.

Jiang et al., 2015 Jiang Y, Lu Y, Li Y, Zhu P, Yang Q. Study on the correlation between methylene tetrahydrofolate reductase gene polymorphism and polycystic ovary syndrome. *Matern Child Heal Care China*. 2015; 30:3831–3.

Jiao, X., Chen, W., Zhang, J., Wang, W., Song, J., Chen, D., Zhu, W., Shi, Y., Yu, X., 2018. Variant alleles of the ESR1, PPARG, HMG2, and MTHFR genes are associated with polycystic ovary syndrome risk in a Chinese population: a case-control study. *Front. Endocrinol*. 9, 504.

Karadeniz M, Erdogan M, Zengi A, Eroglu Z, Tamsel S, Olukman M (2010). Methylenetetrahydrofolate reductase C677T gene polymorphism in Turkish patients with polycystic ovary syndrome. *Endocrine*. 38: 127–133.

Kazerooni T, Ghaffarpasand F, Asadi N et al. Correlation between thrombophilia and recurrent pregnancy loss in patients with polycystic ovary syndrome: a comparative study. *J Chin Med Assoc*. 2013; 76(5):282-288.

Kobashi G, Kato EH, Morikawa M, Shimada S, Ohta K, Fujimoto S et al. (2005). MTHFR C677T Polymorphism and factor V Leiden mutation are not associated with recurrent spontaneous abortion of unexplained etiology in Japanese women. *Semin Thromb Hemost*. 31: 266–71.

Kumar P, Yadav U, Rai V. (2016). Prevalence of glucose 6-phosphate dehydrogenase deficiency in India: An updated meta-analysis. *Egypt J Med Hum Genet*. 2016; 17: 295-302.

Kumar P, Rai V. MTHFR C677T polymorphism and risk of esophageal cancer: An updated meta-analysis. *Egyptian Journal of Medical Human Genetics*. 2018; 19: 273–284.

Kumar P, Rai V. (2018). Catechol-O-Methyltransferase Val158Met polymorphism and susceptibility to Uterine Leiomyoma. *Jacobs Journal of Gynecology and Obstetrics*, 5(1): 043.

Kumar P, Singh G, Rai V. (2020). Evaluation of COMT Gene rs4680 polymorphism as a risk factor for endometrial cancer. *Ind J Clin Biochem*. 35(1):63-71.

Kumar P, Rai V. (2020). Catechol-O-methyltransferase gene Val158Met polymorphism and obsessive compulsive disorder susceptibility: a meta-analysis. *Metab. Brain Dis*. 35:242-251. ISSN 0885-7490.

Lee, K.W., Jeong, Y.M., Lee, S.H., Yoon, T.K., Kwak, I.P., Yoon, S.W., Choi, J.S., Kim, K.H., Han, J.S., Kim, S.D., 2003. The study of 5,10-methylenetetrahydrofolate reductase variation (MTHFR C677T) in infertile females with polycystic ovarian syndrome (PCOS) in Korea. *Kor. J. Fertil. Steril*. 30, 217–222.

Mantel N, and Haenszel W (1959): Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst* 22(4): 719-48.

Mohanty D, Das KC. Effect of folate deficiency on the reproductive organs of female rhesus monkeys: a cytomorphological and cytokinetic study. *J Nutr*. 1982; 112:1565–76.

Naghavi A, Mozdarani H, Garshasbi M, Yaghmaei M. 2015. Prevalence of Methylenetetrahydrofolate Reductase C677T Polymorphism in women with Polycystic Ovary Syndrome in southeast of Iran. *Journal of Medicine and Life* Vol. 8, 2015, 229-232.

Orio F Jr, Palomba S, Di Biase S, Colao A, Tauchmanova L, Savastano S, Labella D, et al. Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2003;88:673–679.

Ożegowska K, Bogacz A, Bartkowiak-Wieczorek J, Seremak-Mrozikiewicz A, Pawelczyk L. Is there an association between the development of metabolic syndrome in PCOS patients and the C677T MTHFR gene polymorphism? *Ginekol Pol.* 2016; 87:246–53.

Palep-Singh M, Picton HM, Yates ZR, Barth JH, Balen AH (2007). Plasma homocysteine concentrations and the single nucleotide polymorphisms in the methionine synthase gene (MTR 2756A>G): Associations with the polycystic ovary syndrome An observational study. *Eur J Obstet Gynecol Reprod Biol.* 138: 180–186.

Qi, Q., Zhang, H., Yu, M., Wang, X., Wang, Z., Xu, L., Wang, J., Mu, H., 2015. Association of methylenetetrahydrofolate reductase gene polymorphisms with polycystic ovary syndrome. *Chin. J. Med. Genet.* 32, 400–404.

Rai V, Yadav U, Kumar P, Yadav SK (2010) Methyletetrahydrofolate reductase polymorphism (C677T) in Muslim population of Eastern Uttar Pradesh, India. *Ind J Med Sci* 64(5): 219-223.

Rai V. (2011). Polymorphism in folate metabolic pathway gene as maternal risk factor for Down syndrome. *Int J Biol Med Res.*, 2(4): 1055-1060.

Rai V, Yadav U, Kumar P (2012) Genotype Prevalence and Allele Frequencies of 5,10-Methylenetetrahydrofolate Reductase (MTHFR) C677T Mutation in two Caste Groups of India. *Cell Mol Biol* 58: OL1695- 701.

Rai V, Yadav U, Kumar P, Yadav SK, Mishra OP. 2014. Maternal Methylenetetrahydrofolate Reductase C677T Polymorphism and Down Syndrome Risk: A Meta-Analysis from 34 Studies. *PLOS ONE* 9 e108552.

Rai V (2014) Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) gene and susceptibility to depression in Asian population: a systematic meta-analysis. *Cell. Mol. Biol.* 2014; 60 (3): 29-36.

Rai V (2014). Methylenetetrahydrofolate reductase gene A1298C polymorphism and susceptibility to recurrent pregnancy loss: a meta-analysis. *Cell Mol Biol.* 27: 27–34.

Rai V (2016) Methylenetetrahydrofolate reductase C677T polymorphism and recurrent pregnancy loss risk in Asian population: a meta-analysis. *Ind J Clin Biochem* 31:402–413

Rai V (2016) Association of methylenetetrahydrofolate reductase (MTHFR) gene C677T polymorphism with autism: evidence of genetic susceptibility. *Metab Brain Dis* 31:727–735.

Rai V (2016) Folate pathway gene methylenetetrahydrofolate reductase C677T polymorphism and Alzheimer disease risk in Asian population. *Indian J Clin Biochem* 31(3): 245-52.

Rai V (2016) Methylenetetrahydrofolate reductase gene C677T polymorphism and its association with ovary cancer. *J Health Med Informat* 7: 3-7.

Rai V (2016) Evaluation of the MTHFR C677T polymorphism as a risk factor for colorectal cancer in Asian populations. *Asian Pac J Cancer Prev* 16(18): 8093–8100.

Rai V, Yadva U, Kumar P (2017) Null association of maternal MTHFR A1298C polymorphism with Down syndrome pregnancy: An updated meta-analysis. *The Egyptian J Med Hum Genet* 18(1): 9-18.

Rai V, Kumar P (2017) Methylenetetrahydrofolate reductase C677T polymorphism and risk of male infertility in Asian population. *Ind J Clin Biochem* 32(3): 253–226 .

Rai V. (2017). Association of C677T polymorphism (rs1801133) in MTHFR gene with depression. *Cell Mol Biol*, 2017;63(6):60-67.

Rai V, Yadav U, Kumar P, Yadav SK, Gupta S (2017) Methylenetetrahydrofolate Reductase A1298C Genetic Variant and Risk of Schizophrenia: an updated meta-analysis. *Indian J Med Res* 145(4):437.

Rai V (2017) Strong association of C677T polymorphism of methylenetetrahydrofolate reductase gene with nosyndromic cleft lip/palate (nsCL/P). *Ind J Clin Biochem* 33(1):5–15.

Rai V, Kumar P (2018) Fetal MTHFR C677T polymorphism confers no susceptibility to Down Syndrome: evidence from meta-analysis. *Egyptian J Med Hum Genet* 19: 53-58.

Rai V, Kumar P (2018) Methylenetetrahydrofolate reductase C677T polymorphism and susceptibility to epilepsy. *Neurological Sciences* doi.org/10.1007/s10072-018-3583-z.

Rai V, Yadav U, Kumar P (2017) Impact of Catechol-O-Methyltransferase Val 158Met (rs4680) Polymorphism on breast cancer Susceptibility in Asian population. *Asian Pac J Cancer Prev* 18 (5): 1243-1250.

Rotterdam, E.A.-S.P., 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). *Hum. Reprod.* 19, 41–47

Schneider JA, Rees DC, Liu YT, Clegg JB. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. *Am J Hum Genet.* 1998;62:1258–60.

Sills ES, Genton MG, Perloe M, Schattman GL, Bralley JA, Tucker MJ. Plasma homocysteine, fasting insulin, and androgen patterns among women with polycystic ovaries and infertility. *J Obstet Gynaecol Res* 2001;27:163–168.

Solomon CG.1999. The Epidemiology of Polycystic Ovary Syndrome. Prevalence and Associated Disease Risks. *Endocrinol Metab Clin North Am* 28(2):247-63.

Spiridonova MG, Stepanov VA, Maksimova NR, Puzyrev VP. Population study of frequency of methylenetetrahydrofolate reductase C677T gene polymorphism in Yakutia. *Genetika.* 2004;40:704–8.

Szafarowska M, Segiet A, Jerzak MM. Methyle notetrahydrofolate reductase A1298C and C677T polymorphisms and adverse pregnancy outcome in women with PCOS. *Neuro Endocrinol Lett*. 2016; 37:141–6.

Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, Kuller L. 1995 Coronary Heart Disease Risk Factors in Women With Polycystic Ovary Syndrome. *Arterioscler Thromb Vasc Biol*. 1995 Jul;15(7):821-6.

Tsanadis G, Vartholomatos G, Korkontzelos I, Avgoustatos F, Kakosimos G, Sotiriadis A, Tatsioni A, Eleftheriou A, Lolis D. Polycystic ovarian syndrome and thrombophilia. *Hum Reprod*. 2002; 17:314–9.

Wild et al., 1985; Talbott et al., 1995; Michelson et al., 1999; Solomon, 1999

Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH (2013) Closing the gap between methodologists and end-users: R as a computational back-end. *J Stat Softw* 49: 1–15.

Wang L, Xu W, Wang C, Tang M, Zhou Y. Methylenetetrahydrofolate reductase C677T polymorphism and the risks of polycystic ovary syndrome: an updated meta-analysis of 14 studies. *Oncotarget*, 2017, Vol. 8, (No. 35), pp: 59509-59517.

Wijeyaratne CN, Balen AH, Barth JH, Belchetz PE (2002). Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? *Clin Endocrinol (Oxf)*. 57: 343–350.

Wilcken B, Bamforth F, Li Z, Zhu H, Ritvanen A, Renlund M, et al. Geographical and ethnic variation of the 677C[T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world-wide. *J Med Genet*. 2003;40:619–25.

Wu W, Shen O, Qin Y, Lu J, Niu X, Zhou Z et al. (2012). Methylenetetrahydrofolate reductase C677T polymorphism and the risk of male infertility: a meta-analysis. *Int J Androl*. 35: 18–24.

Wu, J.B., Zhai, J.F., Yang, J., 2016. Role of methylenetetrahydrofolate reductase C677T and A1298C polymorphisms in polycystic ovary syndrome risk. *Genet. Mol. Res.* 15 (gmr15048570).

Yadav U, Kumar P, Gupta S, Rai V. (2018). Distribution of MTHFR C677T Gene Polymorphism in Healthy North Indian Population and an Updated Meta-analysis. *Ind J Clin Biochem*. 32(4), 399-410. ISSN: 0974-0422.

Yadav U, Kumar P, Rai V. (2016). Role of MTHFR A1298C gene polymorphism in the etiology of prostate cancer: a systematic review and updated meta-analysis. *Egyptian Journal Medical Human Genetics*. 17(2): 141-148.

Yadav U, Kumar P, Rai V. (2018).NQO1 gene C609T polymorphism (dbSNP: rs1800566) and digestive tract cancer risk: A Meta analysis. *Nutrition and Cancer*. 10.1080/01635581.20.

Yadav U, Kumar P, Rai V. (2019). Distribution of Methionine Synthase Reductase (MTRR) Gene A66G Polymorphism in Indian Population. Ind J Clin Biochem. ISSN: 0974-0422. <https://doi.org/10.1007/s12291-019-00862-9>.

Zintzaras E, Ioannis S. 2005. Association between the GLUT1 gene polymorphism and the risk of diabetic nephropathy: a meta-analysis. J Hum Genet (2005) 50:84–91.

Table 1. Details of 24 included studies

Study	Country	Control no.	Case no.	HWE
Glueck et al., 1999	USA	234	41	0.22
Sills et al., 2001	USA	18	36	0.35
Tsanadis et al., 2002	Greece	35	30	0.98
Lee et al., 2003	Korea	100	86	0.66
Orio et al., 2003	Italy	70	70	0.15
Palep-Singh et al., 2007	UK	9	21	0.36
Palep-Singh et al., 2007	UK	16	25	0.61
Choi et al., 2009	Korea	115	227	0.06
Bayram et al., 2010	Turkey	28	30	0
Karadeniz et al., 2010	Turkey	70	86	0
Idali et al., 2012	Iran	100	71	0.42
Jain et al., 2012	India	95	92	0.36
Kazerooni et al., 2013	Iran	60	120	0.007
Jiang et al., 2015	China	122	90	0.36
Naghavi et al., 2015	Iran	196	112	0.14
Qi et al., 2015	China	58	115	0.14
Carlus et al 2016, Indo European	India	100	93	0.36
Carlus et al., 2016, Dravidian	India	156	168	0.58
Geng et al., 2016	China	236	175	0.06
Ozegowska et al., 2016	Poland	99	168	0.49
Sazafarowska et al., 2016	Poland	56	76	0.08
Wu et al., 2016	China	257	244	0.23
Jiao et al., 2018	China	307	336	0.11
Almukhtar and Almohaidi, 2019	Iraq	50	50	0.77

Table 2: Summary estimates for the odds ratio (OR) of MTHFR C677T in various allele/genotype contrasts, the significance level (p value) of heterogeneity test (Q test), and the I^2 metric and publication bias p-value (Egger Test).

Genetic Models	Fixed effect OR (95% CI), p	Random effect OR (95% CI), p	Heterogeneity p-value (Q test)	I^2 (%)	Publication Bias (p of Egger's test)
Allele Contrast (T vs C)	1.28(1.17-1.40), <0.0001	1.18(1.01-1.38), 0.03	<0.0001	61.1	0.07
Co-dominant (Ct vs CC)	1.34(1.17-1.59), <0.0001	1.31(1.04-1.62), 0.017	0.0002	57.92	0.77
Homozygote (TT vs CC)	1.62(1.34-1.96), <0.0001	1.37(1.0-1.89), 0.04	0.0019	53.06	0.05
Dominant (TT+CT vs CC)	1.39(1.23-1.58), <0.0001	1.31(1.07-1.62), 0.008	0.0002	57.99	0.40
Recessive (TT vs CT+CC)	1.32(1.12-1.55), 0.0007	1.10(0.82-1.47), 0.04	0.001	55.06	0.01

Figure 1. Bar diagram showing percentage of C and T allele frequencies in control group of total 24 studies, 16 Asian studies and 8 Caucasian studies.

Figure 2. Random effect Forest plot of homozygote model (TT vs. CC) of total 24 studies of MTHFR gene C677T polymorphism.

Figure 3. Random effect Forest plot of allele contrast model (T vs. C) of total 16 Asian studies of MTHFR gene C677T polymorphism.

Figure 4. Random effect Forest plot of allele contrast model (A vs. G) of total 8 Caucasian studies of MTHFR gene C677T polymorphism.

Figure 5 Funnel plot- precision by log odds ratio for allele contrast model (T vs. C) of total 24 studies of MTHFR gene C677T polymorphism.